Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...
In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $50.00. The company’s shares closed ...
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q4 2024 earnings on Mar 6, 2025. The consensus estimate for Q4 2024 revenue is $44.65 million, and the earnings are expected ...
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $48.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback